CSL Limited (OTCMKTS:CSLLY) Short Interest Update

CSL Limited (OTCMKTS:CSLLY) was the target of a large increase in short interest during the month of February. As of February 28th, there was short interest totalling 20,000 shares, an increase of 189.9% from the February 13th total of 6,900 shares. Currently, 0.0% of the company’s stock are sold short. Based on an average daily trading volume, of 216,000 shares, the days-to-cover ratio is currently 0.1 days.

Analyst Upgrades and Downgrades

Separately, The Goldman Sachs Group upgraded CSL to a “strong-buy” rating in a research note on Thursday, January 16th.

CSL Stock Performance

Shares of CSLLY stock traded up $1.24 during trading hours on Friday, hitting $79.39. 79,327 shares of the company’s stock were exchanged, compared to its average volume of 85,486. The stock’s 50-day moving average is $84.05 and its 200-day moving average is $91.43. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.18 and a quick ratio of 0.97. CSL has a 52 week low of $77.37 and a 52 week high of $109.00.

About CSL

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.